Last updated on November 2019

Phase 1 for Multiple Doses of HM15136 in Obese or Overweight Subjects With Comorbidities

Brief description of study

The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.

Clinical Study Identifier: NCT04167553

Find a site near you

Start Over


San Diego, CA United States
  Connect »